Riociguat
Riociguat, sold as Adempas, is a soluble guanylate cyclase stimulator. The US label lists two uses in adults: persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and pulmonary arterial hypertension (WHO Group 1), in both to improve exercise capacity. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause fetal harm. That risk concerns the unborn child and is recorded separately.
Also called ADEMPAS
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1439816; UNII RU3FE2Y4XI. MeSH has no descriptor for riociguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator, so the record is filed under the class page. The label read is the Bayer HealthCare Pharmaceuticals Inc. label for Adempas, application NDA204819 (approved 2013-10-08 as a new molecular entity in Drugs@FDA), effective 2026-08-13 in openFDA. Chronic thromboembolic pulmonary hypertension has no page of its own in the atlas, so that indication links to the pulmonary hypertension page. The adult indications and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records label indications, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says riociguat stimulates soluble guanylate cyclase, an enzyme in the cardiopulmonary system and the receptor for nitric oxide, and that it both sensitizes the enzyme to nitric oxide and stimulates it directly.
Claims and evidence
Context Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas
- Recipient
- Adult
- Population
- Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Excluded
- None stated
The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.
Applies to Adult Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA204819.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260813.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K29-ADE-LB-04, Q-K29-ADE-LB-05, Q-K29-ADE-LB-06).
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context The developing fetus, for a person taking riociguat during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Excluded
- None stated
The same US label of Adempas carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.
Applies to Fetal The developing fetus, for a person taking riociguat during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA204819.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260813.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-ADE-LB-07).
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (Q-K29-ADE-LB-08).
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of Adempas carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.
Applies to Fetal The developing fetus, for a person taking riociguat during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA204819.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260813.
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-ADE-LB-07).
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (Q-K29-ADE-LB-08).
- Retrieved
- Source effective date
- 2026-08-13
- Source state
- Current
- Version fingerprint
4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension (WHO Group 1) in adults, to improve exercise capacity, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas
The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.
-
Claim, not a settled fact FDA label lists persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) in adults, after surgical treatment or when inoperable, as an indication: Pulmonary hypertension
Applies to Adult Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas
The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.
Record details
- Record id
cardio:riociguat- Content hash
33a4b24de03dc32a1de996a643b59b869214ae1059dae7ca7fcba6a991ba92e4